期刊
RADIOTHERAPY AND ONCOLOGY
卷 139, 期 -, 页码 11-17出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2019.04.008
关键词
FLASH-radiotherapy; Normal tissue protection; Differential effect; Clinical trial
资金
- Fond'action, FNS [FNS/ANR CR32I3L_156924, 31003A_156892]
- ISREC Foundation
- Ecole Normale Superieure de Cachan fellowship (MESR)
- FNS/ANR [CR32I3L_156924]
- Swiss National Science Foundation (SNF) [CR32I3L_156924] Funding Source: Swiss National Science Foundation (SNF)
Over the past decades, technological advances have transformed radiation therapy (RT) into a precise and powerful treatment for cancer patients. Nevertheless, the treatment of radiation-resistant tumors is still restricted by the dose-limiting normal tissue complications. In this context, FLASH-RT is emerging in the field. Consisting of delivering doses within an extremely short irradiation time, FLASH-RT has been identified as a promising new tool to enhance the differential effect between tumors and normal tissues. Indeed, preclinical studies on various animal models and a veterinarian clinical trial have recently shown that compared to conventional dose-rate RT, FLASH-RT could control tumors while minimizing normal tissue toxicity. In the present review, we summarize the main data supporting the clinical translation of FLASH-RT and explore its feasibility, the key irradiation parameters and the potential technologies needed for a successful clinical translation. (C) 2019 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据